Search
Cancer Paid Clinical Trials in Pennsylvania
A listing of 540 Cancer clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
469 - 480 of 540
The state of Pennsylvania currently has 540 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Featured Trial
Ischemic heart disease (IHD) Clinical Study
Recruiting
A clinical study for people that suffer with Ischemic heart disease (IHD)
Conditions:
Ischemic heart disease (IHD)
Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Recruiting
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhancement of current immune checkpoint-based immunotherapy with ALX148, an agent that inhibits CD47 (a trans-membrane protein that is highly expressed on the surface of many solid tumors as compared to normal cells).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Ovarian Cancer
Evaluation of Grief Therapy Approaches for Bereaved Parents
Recruiting
The purpose of this study is to compare three types of support programs for parents who have lost a child. The study will see how these support programs affect participants' grief and depression symptoms. The three support programs are called Meaning-Centered Grief Therapy, Supportive Counseling, and Enhanced Usual Care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Children's Hospital of Philadelphia (Data Collection Only), Philadelphia, Pennsylvania
Conditions: Bereavement, Grief, Cancer
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Recruiting
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/04/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
Recruiting
Epithelial ovarian cancer (OC) is the most lethal gynecologic cancer: nearly 22,000 women are diagnosed with OC in the US annually and 63% are expected to die from their disease. The 5-year overall survival rate is unacceptably low at 20-30%, with \> 50% of patients experiencing recurrence of their disease. Recurrent, platinum-resistant OC is characterized by a low response to chemotherapy (\<10-15%) and poor prognosis, with overall survival estimated to be \<12 months. Thus, there is an urgent... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Epithelial Ovarian Cancer
Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
Recruiting
To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Penn State Health College of Medicine, Hershey, Pennsylvania
Conditions: Breast Cancer, Contrast Enhanced Ultrasound
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Recruiting
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Consultants in Medical Oncology and Hematology, P.C., Broomall, Pennsylvania +1 locations
Conditions: Nonsquamous Non-small Cell Lung Cancer
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
Recruiting
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by slow intravenous (IV) administration in patients undergoing surgical thoracoscopy and resection of lung cancer. Safety is the primary objective of this study, followed by the evaluation of the fluorescence signal as it relates to dose level and dosing time interval.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancers
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Recruiting
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingd... Read More
Gender:
MALE
Ages:
21 years and above
Trial Updated:
11/21/2024
Locations: Doylestown Health, Doylestown, Pennsylvania +3 locations
Conditions: Prostate Cancer
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to:
* Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab
* Learn more about the side effects of BT5528
* Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Recruiting
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose esc... Read More
Gender:
ALL
Ages:
Between 20 years and 99 years
Trial Updated:
11/19/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
Recruiting
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Cri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cervical Cancer by FIGO Stage 2018
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Lehigh Valley Health Network, Bethlehem, Pennsylvania +2 locations
Conditions: Myocarditis Acute, Cancer
469 - 480 of 540